1stOncology™: Cancer Intelligence Service – Page 11624 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Transgene Presents Its Individualized Immunotherapy, TG4050, at The Annual Neoantigen Based Therapies Summit

On November 5, 2020 Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that its Executive Vice President and Chief Scientific Officer, Eric Quéméneur, Pharm.D., PhD, will present today at the virtual 5th Annual Neoantigen Based Therapies Summit (Press release, Transgene, NOV 5, 2020, View Source [SID1234569884]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Presentation

Title: Viral Immunotherapy Meets AI Technology
Session: Clinical Translation – Utilizing Different Delivery Platforms to Enhance Clinical
Timing: November 5th at 11.45 am ET / 5.45 pm CET
Éric Quéméneur, Pharm.D., Ph.D., Executive VP and Chief Scientific Officer of Transgene, said: "Viral immunotherapy constitutes a very promising modality based on harnessing the natural capabilities of the immune system to target cancer cells. TG4050 is an individualized cancer vaccine based on our myvac technology that has the ability to elicit an immune response against up to 30 patient-specific tumor neoantigens. Our partnership with NEC enables us to benefit from its cutting-edge AI capabilities that allows us to select the best combination of neoantigens to include in TG4050 to induce a strong anti-tumor immune response. We are convinced that the success of TG4050, which is at the crossroad of immunotherapy and big data sciences, will herald the start of a new era in the fight against cancer."

The Neoantigen Based Therapies Summit is the leading end-to-end meeting dedicated to delivering the promise of accurate identification, prediction, and validation of neoantigens to develop highly efficacious vaccines and cell therapies.

About TG4050
TG4050 is an individualized cancer vaccine based on the myvac platform; it is based on an optimized viral platform for cancer vaccination and integrates NEC’s artificial intelligence capabilities. This therapeutic vaccine aims at stimulating the immune system of patients to induce a T-cell response against tumor-specific antigenic alterations, called neoantigens. These neoantigens are derived from genomic mutations and selected using NEC’s Neoantigen Prediction System, an advanced AI technology that has already been applied in the field of oncology. TG4050 has been designed to target up to 30 patient-specific neoantigens. Transgene is sponsoring two Phase 1 trials that are expected to deliver a first proof of concept of this virus-based individualized approach.

PCI Biotech: Invitation to third quarter 2020 results presentation

On November 4, 2021 PCI Biotech’s (OSE: PCIB) reported that third quarter 2020 interim report will be released on 11 November 2020 at 07.00 CET (Press release, PCI Biotech, NOV 4, 2020, View Source [SID1234585152]). The interim report and presentation will be made available on www.newsweb.no and on the company’s webpage, www.pcibiotech.com.

A results presentation (in English) will be held through a webcast at 08.30 CET the same day. The webcast can be accessed through www.pcibiotech.com and it will be possible to post questions through the webcast console.

Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period

On November 4, 2020 Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) reported the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price of $225.00 per share in cash, or approximately $13.1 billion (Press release, Bristol-Myers Squibb, NOV 4, 2020, View Source [SID1234573352]). The expiration of the waiting period occurred at 11:59 p.m. EST on November 3, 2020.

Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transaction, which remains subject to the tender of a majority of the outstanding shares of MyoKardia’s common stock, as well as other customary closing conditions. Unless the tender offer is extended, the offer and withdrawal rights will expire at midnight (New York City time), one minute after 11:59 p.m. New York City time, on November 16, 2020.

PerkinElmer to Present at Stifel Virtual Healthcare Conference

On November 4, 2020 PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, reported that the Company will present at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 1:20 p.m. ET (Press release, PerkinElmer, NOV 4, 2020, View Source [SID1234570415]).

Jamey Mock, SVP and chief financial officer of PerkinElmer, will provide an update on the Company and its strategic priorities.

A live audio webcast of the presentation will also be available on the Investors section of the Company’s website at www.perkinelmer.com. A replay of the presentation will be posted on the PerkinElmer website after the event and will be available for 90 days following.

IO Biotech Announces First Patient Dosed in Phase 2 Trial in Head and Neck Cancer Conducted in a Collaboration with Cliniques Universitaires Saint-Luc in Belgium

On November 4, 2020 IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win technology, reported that the first patient has received the first dose in a Phase 2 study (HN1901) investigating activity and safety of peptide-based immunotherapy in the preoperative setting for in-patients with squamous cell carcinoma of the head and neck (SCCHN) (Press release, IO Biotech, NOV 4, 2020, View Source [SID1234570272]). The study is being conducted in collaboration with Cliniques universitaires Saint-Luc in Brussels and is designed as an umbrella trial enabling the testing of several of IO Biotech’s compounds after initial testing of IO102 in a monotherapy setting.

"We are very happy to start this interesting study that will help us to improve our knowledge in immunotherapy for head and neck cancer patients," said Professor Jean-Pascal Machiels, MD, PhD.

"We are excited to start this collaboration led by Professor Jean-Pascal Machiels from Institut Roi albert II Cancer Center of Cliniques universitaires Saint-Luc in Brussels," said Mai-Britt Zocca, PhD, Chief Executive Officer and founder at IO Biotech. "This study will enable IO Biotech to further validate our technology in a new indication, SCCHN, and broaden our scope to a third indication within solid tumors beyond non-small cell lung cancer (NSCLC) and melanoma."

IO Biotech’s lead candidate, IO102, is an Indoleamine 2,3-dioxygenase (IDO) derived immune modulating therapy with a dual mode of action-killing both cancer cells and immune-suppressive cells. IO Biotech’s IDO-derived immune modulating therapies have previously demonstrated both a favorable safety profile and promising anti-tumor activity in its first human clinical trial of heavily pre-treated patients with NSCLC.

About the Study
HN1901 is an open-label, randomized, Phase 2, window of opportunity trial investigating immunological changes in tumor and antitumor activity of vaccine-based immunotherapy in the pre-operative setting of patients with squamous cell carcinoma of the head and neck (SCCHN). This clinical trial is planned to sequentially test IO Biotech’s proprietary immune modulatory vaccines as monotherapy and as multi antigene vaccines at the Cliniques universitaires Saint-Luc in Brussels.

About SCCHN
Squamous cell carcinoma of the head and neck (SCCHN) is one of the most common tumor types worldwide and accounts for more than 550,000 new cases and 380,000 deaths per year. The five-year survival rate for patients suffering from locally advanced head and neck cancer is estimated between 40 and 60 percent depending on the anatomical location of the primary tumor.
IO Biotech is currently conducting studies with T-Win compounds in combination with Pembrolizumab and Nivolumab, both of which are approved for SCCHN.

About T-win Technology Platform
IO Biotech’s proprietary T-win technology platform enables identification of compounds with a dual mechanism of action targeting and directly killing immunosuppressive cells and tumor cells while indirectly activating other T-effectors, leading to strong anti-tumor responses. The company’s compounds are administered as "off-the-shelf" subcutaneous injections, distinguishing these treatments from many immuno-oncology therapies.